<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850628</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP DP-1</org_study_id>
    <nct_id>NCT01850628</nct_id>
  </id_info>
  <brief_title>NSABP Biospecimen Discovery Project</brief_title>
  <official_title>NSABP Biospecimen Discovery Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a biospecimen discovery project that will serve as a pilot for a comprehensive
      'omics approach using fresh core biopsy tissue and blood samples for DNA and protein
      analysis, as well as paired tumor-normal exome DNA and RNA sequencing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at select NSABP sites where investigators are willing to give
      paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination as the initial
      component of neoadjuvant therapy as a pilot for a comprehensive 'omics approach using next
      generation sequencing and protein expression and post-translational modification analysis
      using mass spectrometry (MS) based and Reverse Phase Protein Array-based proteomics. Tumor
      samples will be obtained at baseline and 48 to 72 hours after initial drug treatment to study
      variation in the biological responses to these agents. The study of tumors both before and
      early after the first treatment probes the biological responses to treatment and is rich
      source of predictive biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure variation in biologic response by comprehensive tumor 'omics profiling in patients receiving an upfront regimen containing paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination</measure>
    <time_frame>blood and tissue specimens will be collected at the time of diagnosis; prior to treatment; 48 and 72 hours following first dose of treatment; and following surgery, if tumor remains.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
    <description>Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pertuzumab</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fresh tumor tissue and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with locally advanced, HER2-positive breast cancer from selected sites in the United
        States
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core
             needle biopsy or limited incisional biopsy.

          -  The breast cancer must be HER2-positive based on current ASCO/CAP (American Society of
             Clinical Oncology/College of American Pathologists) Guideline Recommendations for
             Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.

          -  The patient must have a mass in the breast measuring greater than or equal to 2.0 cm
             by physical exam and/or ultrasound that is accessible and safe for repeat biopsy.
             Patients with a diagnosis of inflammatory breast cancer are eligible if there is a
             palpable or detectable breast mass that is accessible and safe for repeat biopsy.

          -  Planned initial treatment with a combination of paclitaxel and trastuzumab or a
             trastuzumab/pertuzumab-based combination. Schedule for paclitaxel/trastuzumab or
             trastuzumab/pertuzumab administration is per the investigator.

        Exclusion Criteria:

          -  Excisional biopsy or lumpectomy performed prior to registration.

          -  Previous therapy with chemotherapy or targeted therapy for any malignancy.

          -  Treatment, including radiation therapy (RT), chemotherapy, and/or targeted therapy,
             administered for the currently diagnosed breast cancer prior to registration.

          -  Other nonmalignant systemic disease that would preclude the patient from receiving
             chemotherapy and targeted therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Gosik, RN, BS</last_name>
    <phone>412-339-5333</phone>
    <email>diana.gosik@nsabp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Allegra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adel Tabchy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Julian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mothaffar Rimawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>National Surgical Adjuvant Breast and Bowel Project (NSABP)</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>HER2 positive (human epidermal growth factor receptor 2)</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Anthracycline therapy</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Operable</keyword>
  <keyword>Biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

